Orencia (Abatacept)

Abatacept, the active ingredient in Orencia, is a selective T‑cell costimulation modulator presented as an injection solution for subcutaneous use. It treats rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis in adult and pediatric patients as a disease‑modifying antirheumatic drug. GNH USA supplies Orencia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orencia acts on the immune pathway that drives inflammatory arthritis, providing disease‑modifying benefits. - Rheumatoid arthritis: reduces joint pain, swelling, and slows structural damage. - Juvenile idiopathic arthritis: improves disease activity and physical function in children. - Psoriatic arthritis: alleviates joint inflammation and associated skin lesions.

Common Side Effects: - Injection site pain or redness - Upper respiratory tract infection - Headache - Nausea - Nasopharyngitis - Fatigue

Serious or Rare Side Effects: - Severe infections such as pneumonia or sepsis - Malignancies including lymphoma - Hypersensitivity reactions (anaphylaxis, rash) - Autoimmune disorders (e.g., lupus‑like syndrome) - Progressive multifocal leukoencephalopathy (rare) - Serious infusion‑related reactions

Before initiating therapy, consider the following precautions: - Monitor for infections: screen for latent tuberculosis and treat active infections before use. - Assess malignancy risk: conduct regular cancer screenings during treatment. - Evaluate vaccination status: avoid live vaccines while on therapy. - Use caution in patients with heart failure: monitor for worsening symptoms. - Pregnancy and lactation: limited data; weigh potential benefits against risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Abatacept may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Live vaccines: contraindicated due to immunosuppression. - Concomitant biologic agents: increased risk of serious infections. - High‑dose corticosteroids or other strong immunosuppressants: may amplify infection risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor for gastrointestinal bleeding. - Other disease‑modifying antirheumatic drugs (DMARDs): observe for additive immunosuppression and adjust laboratory monitoring. - Antiviral agents: assess for potential reduced efficacy.